Stem cell characterization is the study of tissue-specific differentiation. Thera are various type of stem cell such as embryonic stem cell, epithelial stem cell and others. Further, various techniques are used to characterized stem cells such as immunological techniques, used for depiction of different population of stem cells. These techniques are generally based on immunochemistry using staining technique or florescent microscopy. Besides, stem cells characterization and analysis tools are used against target chronic diseases. In 2014, the San Diego (UCSD) Health System and Sanford Stem Cell Clinical Center at the University of California announced the launch of a clinical trial, in order to assess the safety of neural stem cellbased therapy in patients with chronic spinal cord injury.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/31444

The factors driving the growth of stem cell characterization and analysis tools market due to increasing chronic disorders such as cancer, a diabetes and others. In addition, increasing awareness about among people about the therapeutic potency of stem cells characterization in the management of effective diseases is anticipated to increase the demand for stem cell characterization and analysis tools. Further, there are various technologies such as flow cytometry which is used to characterize the cell surface profiling of human-bone marrow and other related purposes are expected to increase the growth of stem cell characterization and analysis tools market. In addition, increasing investment by private and public organization for research activities are likely to supplement the market growth in near future.

On the other hand, the unclear guidelines and the technical limitation for the development of the product are expected to hamper the growth of stem cell characterization and analysis tools market.

Rapid increase in corona virus all around the world is expected to hamper the growth of stem cell characterization and analysis tools market. The virus outburst has become one of the threats to the global economy and financial markets. The impact has made immense decrease in revenue generation in the field of all healthcare industry growth for the market in terms of compatibility and it has led in huge financial losses and human life which has hit very hard to the core of developing as well as emerging economies in healthcare sector. It further anticipated that such gloomy epidemiological pandemic environment is going to remain in next for at least some months, and this is going to also affect the life-science market which also include the market of stem cell characterization and analysis tools market.

Based on the Products and Service Type, stem cell characterization and analysis tools market are segmented into:

Based on the Technology, stem cell characterization and analysis tools market are segmented into:

Based on the Applications, stem cell characterization and analysis tools market are segmented into:

Based on the End User, stem cell characterization and analysis tools market are segmented into:

Based on the segmentation, human embryonic stem cell is expected to dominate the market due to their indefinite life span and higher totipotency as compared to other stem cells. Further, on the basis of technology segmentations, cell production is anticipated to increase the demand for stem cell characterization and analysis tools due to their emerging applications for stem cells in drug testing in the management of the effective diseases. Furthermore, on the basis of application segmentations, oncology is expected to show significant growth rate due to increase in the number of pipelines products for the treatment of cancers or tumors. Based on the end user, pharmaceutical and biotechnology companies are expected to dominate the market due to rising global awareness about the therapeutics research activities.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/31444

Geographically, the global stem cell characterization and analysis tools market is segmented into regions such as Latin America, Europe, North America, South Asia, East Asia Middle East & Africa and Oceania. North America is projected to emerge as prominent market in the global stem cell characterization and analysis tools market due to growing cases of target chronic diseases and increasing investments for research activities. Europe is the second leading region to dominate the market due to technological advancement and also surge in therapeutic activities, funded by government across the world. Asia-pacific is likely to witness maximum growth in near future due to increasing disposable income and with the development of infrastructure.

Some of the major key players competing in the global stem cell characterization and analysis tools market are Osiris Therapeutics, Inc., Caladrius Biosciences, Inc., U.S. Stem Cell, Inc., Astellas Pharma Inc., TEMCELL Technologies Inc., BioTime Inc., Cellular Engineering Technologies Inc., Cytori Therapeutics, Inc., and BrainStorm Cell Therapeutics Inc.

Original post:
Impact of COVID 19 pandemic on Stem Cell Characterization and Analysis Tools Market Structure and Its Segmentation - 3rd Watch News

Tanya Klowden is a physicist with a background in design and history whose work is focused on identifying the works and telling the stories of unrecognized and underappreciated artists and voices in history.

Over the past several weeks, the outcries over the killing of George Floyd in Minneapolis, combined with recent killings of Ahmaud Arbery in Brunswick, Georgia and Breonna Taylor in Louisville, Kentucky have grown to a dull roar, finally focusing our nation on the tremendous risk of violence and death borne on a daily basis by people of color within this country. As our broader population has begun to address the widespread and persistent violence that has plagued minority communities for generations, medical researchers in the past few weeks have expressed significant concern over another urgent threat, finding a much higher death rate from COVID-19 within our African-American communities here in California and in the country as a whole.

We have observed over the past several weeks what we already knew, or at least should have known, that disease falls hardest on the most underprivileged and that minorities in particular, independent of their economic status, are at a higher risk of death. The non-partisan APM research lab released figures showing that African-Americans have died from COVID-19 alone at a rate of 50.3 per 100,000 people- well over twice the rates for whites (20.7), Latinos (22.9) and Asian Americans (22.7). There are several reasons for this, none of which is biological susceptibility. Most of the difficulties are direct impacts of systematic racism, so it is important we look at some of these issues to better understand why they are amplifying, rather than suppressing, the impact of disease.

In fact, per capita public health spending (and public education spending) is measurably lower in most regions in this country with a significantly higher African-American population. While lower public health spending in your region will result in poorer outcomes all by itself, medical professionals find that they are also struggling with high levels of distrust from minorities, particularly from those in the older generations. The more privileged you are, the less likely you are to have ever been treated by, and simultaneously not trusted, your doctor. As a privileged person, you probably learned about the Hippocratic oath at a young age and always accepted that your doctor made a promise to help, not harm, in all circumstances.

To help place you in the mindset of someone who has been given no reason to trust doctors and every reason to fear them, I have for you the story of Henrietta Lacks. Henrietta Lacks was an African-American woman born in 1920. She worked as a tobacco farmer and was a mother from an early age. When she was thirty, after giving birth and hemorrhaging severely after, she was diagnosed with cervical cancer. She was given routine (at the time) treatment for her cancer and instructed to follow up with the hospital. During followup treatment she was admitted to the hospital at her request due to severe abdominal pain and remained hospitalized until her death two months later, in 1951.

For a very long time, that seemed to be the end of Henrietta Lacks story. What is both remarkable and deeply problematic is that her contributions to society did not end at her death. Henrietta Lacks has saved your life and my life and she is absolutely on the front-line fighting against Covid-19 right now.

During her treatments, healthy and cancerous tissue was sampled from her body without her knowledge or consent. Those cells were cultured and displayed the unique ability to reproduce endlessly and remain alive within a culture for far longer than any previous cell lines medicine had studied. Anonymized simply as the HeLa cell line, they became the standard for human medical research; Henriettas bodyweight in cell mass being grown millions of times over (over 50 million metric tons as of 2011) to meet the insatiable needs of modern medicine. Without Henrietta Lacks, there would have been no California Stem Cell Initiative and no California Institute for Regenerative Medicine, among numerous efforts that have enabled the rise of biotechnology and life science research in the state.

Not only was Henrietta herself never able to give consent to this or any use, her family did not even know of the existence and tremendous spread of her genetic material until early in the 21st century, by which time HeLa usage was so widespread there was no ability to grant or withdraw consent. As of 2013, the only gain her family has secured from her legacy is a promise from the NIH of acknowledgement in subsequent scientific papers and two seats on a panel regulating access to her DNA sequence going forward. While Henrietta Lacks story is extraordinary, her treatment by the medical community is in many ways typical of the healthcare African Americans have experienced over the last 70 years, with African-American healthcare prior to that being literally the stuff of nightmares. Within the past century, there are plentiful accounts of forced sterilizations, of being placed in trials without their knowledge or consent, of being accused of lying when recounting their history or symptoms, of being lied to, and even of being straight-up experimented on as an expendable population. In light of this history, it becomes much clearer why many minority groups would push back when told to sacrifice their jobs to keep others healthy, to stay home when the grocery store shelves are emptying, to leave the hospital when a relative is struggling for breath with no way of knowing what will happen to their loved one inside the hospital doors once they are not there to watch over them.

When this is compounded by widespread suspicion of any African-American individual wearing a mask who walks their dog or goes to a market to shop, the significant risk of grave harm is only compounded further. While the loudest voices against masks have been those of angry white people upset at the disruption of their privilege, minorities are very aware that at the intersection of masks, profiling, and persons of color the health risks of mask wearing are very real. In recent weeks, we have already seen violence inflicted on African-Americans for looking suspicious by being in public while following CDC guidelines. In April, a succinct tweet circulated stating it bluntly. I dont want to die and on the other hand, I dont want to die. Jokes from the privileged about committing crimes, being nefarious, or shady need to stop. None of that does what is urgently needed, which is to normalize mask usage among all groups so that it can help slow the spread of disease. We can instead treat people of color within our communities with respect, and listen to their perspectives in navigating through this global health crisis.

The pain and death we are inflicting on the African-American community may be far more apparent now, but we need to recognize and address the fundamental wrongs that extend far beyond policing, and even healthcare. We are not going to fix this environment overnight, but we definitely do not need to make it worse. Right now our minority communities urgently need funding. Public health funding is absolutely critical but these communities also need funding to provide masks and other desperately needed protective equipment to every individual who must spend long hours working in public spaces, funding to keep people securely housed, with ample access to healthy food, funding for widespread, low-cost (or free) internet connectivity so that the poorest children within our society can continue to be educated through distance-learning alongside their more privileged peers. Looking further ahead, we desperately need to nurture a new generation of African-American scientists and doctors by reaching out to students early, while they are still in primary school, and we need to rebuild bridges to the community with better, more accessible and trusted healthcare. Weve already collectively inflicted plenty of harm, we can at least start to make steps towards making their situation better.

Follow this link:
Inequality in COVID-19 Has Other Dangerous Consequences - Fox and Hounds Daily

SAN FRANCISCO, June 29, 2020 /PRNewswire/ --Entitled "Randomized, Double Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction: rationale, design and first interim analysis", the presentation provides an initial insight into patient outcomes of the trial that is currently ongoing in multiple centers. Patients included in this trial experienced a severe form of Myocardial Infarction known as STEMI. Soon after the initial intervention to re-establish adequate blood flow to the coronary arteries, patients begin a two-week treatment with Recardio's dutogliptin, a small molecule that enables sustained homing of mobilised stem cells to the site of cardiac injury. By releasing paracrine factors, stem cells have been shown to have significant repair and regenerative effects that improve healing and recovery of cardiac function after the infarction.

More information about the clinical program is available by visiting the "clinicaltrials.gov" website at the following link:https://clinicaltrials.gov/ct2/show/NCT03486080

About Recardio

Recardio Inc. is a clinical-stage life science company focusing ontherapies for cardiovascular, oncology and infectious diseases. The company is located in San Francisco, California, and hasoperations in the USA and Europe.The company's lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines like SDF-1, a protein that is critical for cardiac regeneration. In addition to its current Phase 2 cardiovascular clinical program, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival.

For more information, visit:http://www.recardio.eu/or contact[emailprotected]

SOURCE Recardio

LEARN HOW WE APPROACH REGENERATIVE CARDIAC MEDICINE OF TOMORROW

View post:
Interim Analysis of Recardio's Phase II Clinical Trial to Be Presented at the 2020 Congress of the European Society of Cardiology - PRNewswire

By Alex Kormann Star Tribune

June 29, 2020 11:29am

Taylor Bustos rubbed her newly shaved head in the dimly lit basement of her temporary Rochester home as an intrepid thought seized her. This better freaking be the last time.

Two years ago, Bustos was happy. She was 20, recently married and had just found out she was pregnant with her first child. Taylor and her husband, Mark, 21, envisioned moving from Duluth to California and raising half a dozen kids. But those plans would have to wait.

Five months into her pregnancy, Bustos felt a lump on her neck. On Oct. 5, 2018, just a month after giving birth to her son, Solomon, she was diagnosed with nodular sclerosis classical Hodgkins lymphoma. Its the most common type of Hodgkins lymphoma, a cancer that affects the bodys immune system.

I was told, This is the good cancer, its curable, Bustos said. She underwent six months of chemotherapy at St. Lukes Radiation Oncology Associates in Duluth and was declared in remission in April 2019. After that, life went pretty much back to normal.

But last November, just before her first follow-up PET CT scan, Bustos prepared for the worst. A few weeks earlier, she had felt the lump in her neck return.

Soon later, she was back at St. Lukes, prepared to receive whatever news may come. Mark tossed a bright pink ball to Solomon to distract the boy and himself from the mounting anxiety as they waited for what felt like an eternity in the small examination room.

The young father was also trying to manage his stress from recently learning he was being laid off from his construction job. The doctor finally stepped in.

Taylor Bustos got a follow-up PET CT scan in her first follow-up scan since being declared cancer free six months earlier. It was not good news. More chemotherapy. She slept through most of her treatments as the potent drugs worked to rid her body of cancer. When Taylors hair started to fall out in clumps, Mark shaved her head. But again, her family didnt let her do this alone.

Im sitting there with a one-year-old and my husband of two years and theyre telling me at 22 years old that I have cancer for the second time, Bustos said.

She had gone into the meeting with the mind-set that she would never endure chemotherapy again. It was physically and mentally unlike any other suffering Ive ever gone through in my life and I didnt want to willingly say yes to going back there, Bustos said.

After a week of thinking and praying, Bustos stumbled across a Facebook post from a friend who had recently lost his father in a house fire. His words resonated so deeply with her that she decided she couldnt just lay down and die. This cancer could kill me, but dont I want my sweet son to know I tried? she said.

Once again, she went in for treatments, then slept for three days. The big difference this time was that, to make sure the cancer never came back, she was going to have to follow the doctors next recommendation.

On March 2, the Bustos family picked up and moved 200 miles across the state to Rochester for three months where she would undergo some of the most toxic chemotherapy available at the Mayo Clinic. The mix was so potent that she had to first undergo a stem cell collection; those stem cells would be transplanted afterward to regrow her immune system and other healthy cells decimated by the chemo.

Marks layoff, which at first seemed like a disaster, was now a gift. He could assume a larger role as the family caretaker. Some people might call that luck, but the Bustoss dont believe in luck. For them, it was an act of God.

When it came time to move, Taylors parents, Pam and Jerry, who live across the street from the Bustoses in Duluth, moved with them to help take care of Solomon and Taylor.

It really wasnt a difficult decision, said Jerry, who is a warehouse operator at a Duluth paper supply business.

For me, he said, I would do whatever it takes to get her healthy.

Above left, Taylor entered Mayo Clinic for a week of continuous chemotherapy treatment in the middle of the COVID-19 pandemic. When she got home, cuddles from son Solomon and sleeping in her own bed were two longed-for moments.

Their family squeezed as much as they could into their two cars, boxes stacked to the roof, rendering the rearview mirror useless. The family settled into a small house only a mile away from the Mayo Clinic.

Just over a week later, COVID-19 hit.

We knew Id have a weakened immune system and wed have to quarantine, Bustos said, but suddenly the whole world had to quarantine, too.

They stayed closely connected with their church through video chat and live streams. In solidarity, her entire family shaved their heads along with Bustos.

A little over a month after moving, Bustos prepared for her most difficult round of chemotherapy. All the effects of normal chemo, including nausea, exhaustion, loss of appetite and body pain would be amplified. And because of the coronavirus, she would be doing it alone. She packed her keyboard piano, a weeks worth of clothes, a few mementos from home and headed to the hospital. She would have to stay in a heavily filtered room by herself for a full week as she underwent treatment.

Masked nurses came and went as Bustos tried to picture what they looked like under all the PPE. Most days, she felt immensely lonely and sad. Originally, she was told shed be able to go home to see her family for one hour per day. The pandemic scrapped those plans. I would cry and nurses couldnt put their hand on my shoulder to tell me, Its OK, because of the coronavirus, Bustos said.

When she was finally able to return to her family a full week later, Bustos was ecstatic. To be able to be hugged was a very welcome relief from despair, she said.

She began to try and process what had happened to her over the last five months. She felt distant from and misunderstood by nearly everyone around her. It can look like its going well from the outside but when you literally want to die, the emotional side of things needs to be handled, she said.

Bustos has since begun therapy and is taking anti-depressants to help manage her mental pain.

As the family moved out of Rochester, the snow was gone. Birds chirped and flowers bloomed; a sign of rebirth and a new beginning.

When they pulled up in front of their apartment in Duluth, chalk drawings graced their sidewalk welcoming them home. Their front door was covered in balloons and a welcome banner was strung across the door frame, all put together by members of Bustoss church youth group.

Bustos collapsed on her old bed. She thought shed feel different in their own apartment, but it oddly felt the same. She had come to realize that home was no longer a physical space. Cancer changed that.

Home for me has become Mark and Solomon, she said, and so whether were in Rochester, Duluth or Timbuktu, Im home when Im with them.

Alex Kormann on Instagram: @alexkormann12

See original here:
In the middle of a pandemic, a young Minnesota mother fights her second cancer diagnosis - Minneapolis Star Tribune

RYE BROOK, N.Y., July 1, 2020 /PRNewswire/ --Seeking to ignite the next major breakthroughs to treat blood cancers, The Leukemia & Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group today announced more than $6.75 million awarded to nine of the most exceptional scientists in the field.

The innovative Blood Cancer Discoveries Grant Program is designed to encourage researchers with deep experience in the blood cancers to conduct critical basic research in hopes of unleashing the next wave of novel approaches to treating leukemia, lymphoma, myeloma and myelodysplastic syndromes; together, these cancers are the 2nd leading cause of cancer deaths in the U.S.

"Over our 70-year history, The Leukemia & Lymphoma Society has been at the forefront of revolutionary cancer treatments from the early days of chemotherapy and stem cell transplantation to the leading edge discoveries of immunotherapy and precision medicine; our investment in research is nearly $1.3 billion over that time," said Lee Greenberger, LLS's chief scientific officer. "With this new initiative, LLS maintains its role as a driver of innovation, supporting early stage research to propel discoveries that might lead to the next generation of treatments and cures, and help accelerate promising therapies to patients."

The grants are awarded to researchers seeking to understand the biological underpinnings of various blood cancers, what causes them to develop and grow, or become resistant to treatments. Each project will be supported by an award of $750,000 over a three-year period.

"In science, collaboration can accelerate the pace of achievement," said Michele Cleary, Ph.D., CEO ofThe Mark Foundation for Cancer Research."Similarly, this three-way partnership among foundations will accelerate our understanding of cancer biology by empowering some of the brightest scientists to simultaneously probe unique but challenging areas of unmet need. We look forward to the discoveries that will result from these efforts."

Added Kathryn Richmond, Ph.D., MBA, director of the Frontiers Group, a division of the Allen Institute,"Our organizationis committed to pushing the boundaries of bioscience and accelerating discoveries to make a difference for humankind, and we believe these grants will be a catalyst that will spark innovative new directions in blood cancer research."

"We are grateful that the Frontiers Group and Mark Foundation have aligned with us to fund some of the greatest minds in cancer discovery," said LLS's Greenberger. "Collaboratingwith foundations who share a common goal of fueling leading-edge research to advance cures and better, safer treatments for cancer patients is critical to advancing our mission."

The Blood Cancer Discoveries Grant Program recipientsare:

Robert Bradley, Ph.D. Fred Hutchinson Cancer Research Center Dr. Bradley is investigating the mutations in the SF3B1 protein and their connection with myelodysplastic syndromes (MDS) and leukemias, and exploring this protein as a therapeutic target.

Catriona Jamieson, M.D., Ph.D. University of California San Diego Dr. Jamieson is examining the role of two enzymes (APOBEC3 and ADAR1) known to mutate DNA and RNA and their role in AML and disease relapse, particularly in elderly patients.

Ronald (Ron) Levy, M.D. Stanford University School of Medicine Dr. Levy is investigating a pre-clinical "off-the-shelf" CAR (chimeric antigen receptor) T-cell immunotherapy approach where the CAR cells are generated directly in the patient's body.

Ravindra (Ravi) Majeti, M.D., Ph.D. Stanford University School of Medicine Dr. Majeti is generating cell-based models to test the progression of preleukemic cells into acute myeloid leukemia (AML). His lab will use these models to test potential therapies and the role of the microenvironment in disease progression.

Markus Mschen M.D., Ph.D. City of Hope Dr. Mschen studies mechanisms of tumor-initiation in B-cell malignancies, including acute lymphoblastic leukemia, mantle cell lymphoma and diffuse large B-cell lymphoma. These studies focus on negative regulators of the WNT/b-catenin pathway as potential diagnostic marker and therapeutic target.

Susan Schwab, Ph.D. New York University Dr. Schwab is examining the mechanism of T-cell acute lymphoblastic leukemia (T-ALL) cells that allow them to enter and accumulate in the central nervous system when the disease spreads to the brain.

Margaret Shipp, M.D. Dana-Farber Cancer Institute/ Harvard Medical School Dr. Shipp and her colleague, Scott J. Rodig, MD, Ph.D.,are mapping the immune microenvironment in classical Hodgkin lymphoma.

Robert Signer, Ph.D. University of California San Diego Dr. Signer is investigating how the biological process of building defective proteins (inaccurate protein synthesis) plays a role in the development of acute myeloid leukemia (AML) in the hopes of developing targeted therapies to treat this condition.

Daniel T. Starczynowski, Ph.D Cincinnati Children's Research Foundation Dr. Starczynowski is investigating the role and potential therapeutic benefit of targeting of a protein called UBE2N in acute myeloid leukemia (AML).

Click herefor more details on each awardee.

About The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is a global leader in the fight against cancer. The LLS mission: cure leukemia, lymphoma, multiplemyeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in Rye Brook, NY, LLS has chapters throughout the United States and Canada. To learn more, visitwww.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m., ET.

The LLS Children's Initiative: Cures and Care for Children with Cancer TheLLS Children's Initiativeis a $100 million multi-year effort to take on children's cancer through every facet of LLS's mission: research, patient education and support and policy and advocacy. The LLS Children's Initiative includes: more pediatric research grants, a global precision medicine clinical trial, expanded free education and support services for children and families and driving policies and laws that break down barriers to care. To learn more, visitwww.lls.org/childrens-initiative.

About The Mark Foundation for Cancer Research The Mark Foundation for Cancer Research actively partners with scientists to accelerate research that will transform the prevention, diagnosis, and treatment of cancer. The Mark Foundation fulfills its mission by supporting groundbreaking science carried out by individual investigators, multi-disciplinary teams, and inter-institutional collaborations in the United States and across the globe. Recognizing the obstacles that prevent scientific advances from improving patient outcomes, The Mark Foundation maintains a nimble, high-impact approach to funding research through grants for basic and translational cancer research and investments in early-stage companies that bridge the gap between bench and bedside. Since its launch in 2017, the Mark Foundation has awarded over $90 million in grant funding to over 50 institutions in the U.S., the U.K. and Europe. To learn more, visit http://www.themarkfoundation.org

About The Paul G. Allen Frontiers Group The Paul G. Allen Frontiers Group, a division of the Allen Institute,is dedicated to exploringthe landscape of bioscience to identify and foster ideas that will change the world. The Frontiers Group directs funding through award mechanisms to accelerate our understanding of biology, including: Allen Discovery Centers at partner institutions forleadership-driven, compass-guided research, and Allen Distinguished Investigatorsforfrontier explorations with exceptional creativity and potential impact.The Paul G. Allen Frontiers Groupwas foundedin 2016 by the late philanthropist and visionary Paul G. Allen. For more information, visit allenfrontiersgroup.org.

Contact: Andrea Greif [emailprotected] (914) 821-8958

SOURCE The Leukemia & Lymphoma Society (LLS)

https://www.lls.org

Read the original here:
The Leukemia & Lymphoma Society, The Mark Foundation for Cancer Research and The Paul G. Allen Frontiers Group Partner to Award $6.75M in New...